Zacks Investment Research Downgrades AC Immune (ACIU) to Hold

Share on StockTwits

AC Immune (NASDAQ:ACIU) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Tuesday.

According to Zacks, “AC Immune SA is a biopharmaceutical company. It develops, discover and design novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases. The Company’s pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta and Morphomer alpha-syn which are in clinical trial. AC Immune SA is based in Lausanne, Switzerland. “

A number of other brokerages also recently issued reports on ACIU. BidaskClub downgraded AC Immune from a “hold” rating to a “sell” rating in a report on Thursday, August 16th. ValuEngine raised AC Immune from a “hold” rating to a “buy” rating in a report on Friday, July 6th. Finally, HC Wainwright set a $18.00 price target on AC Immune and gave the company a “buy” rating in a report on Thursday, August 9th. One analyst has rated the stock with a sell rating, three have given a hold rating and one has assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $14.00.

Shares of ACIU opened at $7.98 on Tuesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.65 and a quick ratio of 9.65. The company has a market capitalization of $526.90 million, a P/E ratio of -26.60 and a beta of 2.22. AC Immune has a 52-week low of $7.16 and a 52-week high of $17.40.

AC Immune (NASDAQ:ACIU) last announced its quarterly earnings results on Wednesday, August 8th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.23) by $0.04. The firm had revenue of $2.03 million during the quarter, compared to the consensus estimate of $1.92 million. AC Immune had a negative return on equity of 25.44% and a negative net margin of 133.00%. On average, sell-side analysts predict that AC Immune will post -0.93 EPS for the current fiscal year.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.

Featured Story: Dow Jones Industrial Average (DJIA)

Get a free copy of the Zacks research report on AC Immune (ACIU)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

MarteXcoin Trading Down 9.2% Over Last Week
MarteXcoin Trading Down 9.2% Over Last Week
Bitcoin Private Trading Down 5.8% Over Last 7 Days
Bitcoin Private Trading Down 5.8% Over Last 7 Days
Scpharmaceuticals Inc  Given $12.67 Consensus Target Price by Brokerages
Scpharmaceuticals Inc Given $12.67 Consensus Target Price by Brokerages
$0.89 Earnings Per Share Expected for Sensient Technologies Co.  This Quarter
$0.89 Earnings Per Share Expected for Sensient Technologies Co. This Quarter
Pretium Resources  Stock Rating Reaffirmed by Canaccord Genuity
Pretium Resources Stock Rating Reaffirmed by Canaccord Genuity
Education Ecosystem Market Cap Reaches $2.06 Million
Education Ecosystem Market Cap Reaches $2.06 Million


Leave a Reply

© 2006-2018 Ticker Report. Google+.